Validation of the Pooled Cohort equations in a long-term cohort study of Hong Kong Chinese

Journal of Clinical Lipidology

Volumn 9, Issue 5, 2015, Pages 640-646.e2

  Lee, Chi Ho ^a   Woo, Yu Cho ^a   Lam, Joanne K Y ^a   Fong, Carol H Y ^a   Cheung, Bernard M Y ^a,b   Lam, Karen S L ^a,b   Tan, Kathryn C B ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiovascular disease; Cholesterol; Primary prevention; Statins; Validation studies

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; FRAMINGHAM RISK SCORE; HONG KONG; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POOLED COHORT EQUATION; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; VALIDATION STUDY; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; MEDICAL SOCIETY; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; AGED; AMERICAN HEART ASSOCIATION; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HONG KONG; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84941418248     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.06.005     Document Type: Article

References (19)

1. D.C. Goff Jr., D.M. Lloyd-Jones, G. Bennett, and et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 25 Suppl 2 2014 S49 S73
2. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 25 2002 3143 3421
3. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 25 Suppl 2 2014 S1 S45
4. P. Muntner, L.D. Colantonio, M. Cushman, and et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations JAMA 311 14 2014 1406 1415
5. P.M. Ridker, and N.R. Cook Statins: new American guidelines for prevention of cardiovascular disease Lancet 382 9907 2013 1762 1765
6. Asia Pacific Cohort Studies C F. Barzi, A. Patel, D. Gu, and et al. Cardiovascular risk prediction tools for populations in Asia J Epidemiol Community Health 61 2 2007 115 121
7. J. Liu, Y. Hong, R.B. D'Agostino Sr., and et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study JAMA 291 21 2004 2591 2599
8. R.B. D'Agostino Sr., R.S. Vasan, M.J. Pencina, and et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study Circulation 117 6 2008 743 753
9. E.D. Janus Epidemiology of cardiovascular risk factors in Hong Kong Clin Exp Pharmacol Physiol 24 12 1997 987 988
10. R.B. D'Agostino, and B.H. Nam Evaluation of the performance of survival analysis models: discrimination and calibration measures Handbook of Statistics 23 2003 1 25
11. G.M. Allan, S. Garrison, and J. McCormack Comparison of cardiovascular disease risk calculators Curr Opin Lipidol 25 4 2014 254 265
12. M.J. Pencina, A.M. Navar-Boggan, R.B. D'Agostino Sr., and et al. Application of new cholesterol guidelines to a population-based sample N Engl J Med 370 2014 1422 1431
13. M. Kavousi, M.J. Leening, D. Nanchen, and et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort JAMA 311 14 2014 1416 1423
14. E. Lee, S. Ryan, B. Birmingham, and et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment Clin Pharmacol Ther 78 4 2005 330 341
15. M. Hu, and B. Tomlinson Pharmacogenomics of lipid-lowering therapies Pharmacogenomics 14 8 2013 981 995
16. B.K. Birmingham, S.R. Bujac, R. Elsby, and et al. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur J Clin Pharmacol 71 3 2015 341 355
17. J.K. Liao Safety and efficacy of statins in Asians Am J Cardiol 99 3 2007 410 414
18. Group HTC HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 17 2013 1279 1291
19. A.P. DeFilippis, R. Young, C.J. Carrubba, and et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort Ann Intern Med 162 2015 266 275